Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.48 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | SELE | P16581 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5123734 | 0.93 | APP (0.48) | PDE5AICAM1SELEVCAM1 | |
| SCHEMBL5114944 | 0.88 | PDE5A (0.51) | PDE5ABCDIN3D | |
| SCHEMBL5118432 | 0.88 | ICAM1 (0.48) | PDE5AICAM1SELEVCAM1 | |
| SCHEMBL5123467 | 0.87 | PDE5A (0.50) | PDE5ABCDIN3D | |
| SCHEMBL5121978 | 0.85 | PDE5A (0.52) | PDE5ABCDIN3D | |
| SCHEMBL5118618 | 0.85 | PRKCI (0.59) | PDE5ABCDIN3D | |
| SCHEMBL5123252 | 0.84 | PDE5A (0.46) | PDE5AICAM1SELEVCAM1 | |
| SCHEMBL5124230 | 0.84 | PDE5A (0.42) | PDE5ABCDIN3DICAM1SELEVCAM1 | |
| SCHEMBL5119239 | 0.83 | PDE5A (0.51) | PDE5ABCDIN3D | |
| SCHEMBL6711498 | 0.83 | PDE5A (0.41) | PDE5ABCDIN3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-1875023-A | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2006-12-06 | — | — | CN | disclosed |
| EP-0934321-B1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 2003-08-06 | — | — | EP | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| CN-1081638-C | Thienopyrimidine compounds | MERCK PATENT GMBH (DE) | 2002-03-27 | — | — | CN | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6130223-A | Thienopyrimidine with phosphodiesterase V inhibiting effect | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-10-10 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| US-5948911-A | Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| CN-1227560-A | Thienopyrimidines | MERCK PATENT GMBH (DE) | 1999-09-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | PDE5A 2002/4885BCDIN3D 1161/4885ICAM1 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.